skip to content
Detailed Quote
5i Report

Review of Knight Therapeutics

SEP 19, 2018 - Specialty Pharmaceutical company focused on later stage commercialization of drugs. The company continues to hold on to a high balance of cash, waiting for the right opportunity. Despite strong fundamentals and management, the increased opportunity cost and stock trading sideways justify the rating to be downgraded one notch to 'B+'.

Download Report
Company Profile
Interactive Chart
Key Ratios
Top Banner 5i Free Trial
Analyst Recommendations
5i Recent Questions

Q: I own all of these in equal weighting (7% each). Down quite a bit on NFI. Just seeing if I should keep it and give it the long term (10 years) to provide a good return or sell because there is a better company to replace it with for a better long term performance at this point. Any other recommendations as I do have some cash side lined at this point (30%).

Read Answer Asked by Ryan on May 16, 2019
CMS Buy Now
Share Information
News and Media